• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rifaximin - Key patent, SPC, and data exclusivity expiry (44 country coverage) Product Image

Rifaximin - Key patent, SPC, and data exclusivity expiry (44 country coverage)

  • Published: April 2014
  • Region: Global
  • GenericsWeb

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Colesevelam
Colesevelam indications: Adjucntive therapy to diet for reducing elevated low-density lipoprotein cholesterol (LDL-C) or cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa), optionally in combination with a HMG-CoA reductase inhibitor; Adjunctive therapy to diet and exercise for improving glycemic control in patients with type 2 diabetes mellitus; Treatment of primary hypercholesterolaemia in combination with Ezetimibe, with or without a statin
Colesevelam innovator: Daiichi Sankyo (Welchol); Genzyme (Cholestagel); Valeant (Lodalis)

Examples of information found in this online report include:
- Includes key patent publications for 44 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by READ MORE >

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

- Includes key patent publications for 44 countries
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial patent documents and national registries enabling data verification

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos